Hematological Disorders

pharma-news-for-eisai-travere-sanofi

Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Approves Eisai & Biogen’s LEQEMBI IQLIK for Maintenance Treatment of Early Alzheimer’s; Travere Therapeutics Gains FDA Nod for FILSPARI REMS Update in IgA Nephropathy; Vanda Pharmaceuticals’ VGT-1849B Granted FDA Orphan Drug Status for Polycythemia Vera; Teva Launches First FDA-Approved Generic SAXENDA for Weight Loss; Sanofi’s WAYRILZ Gets FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia

Explore More...
medtech-news-for-esaote-medmira-moleculight

Esaote’s MyLab™ A50 and A70 Ultrasound Systems Achieve FDA 510(k) Clearance; Health Canada Approves MedMira’s Reveal® TP Rapid Test for Syphilis; MolecuLight’s Transformative Effect on Wound Care Confirmed by Large Randomized Trial; Arctx Medical’s ACC Kit Receives FDA IDE Approval and Dr. Robert Kieval Appointed CEO; Quest’s Haystack MRD Test Awarded FDA Breakthrough Device Designation for Post-Surgical Colorectal Cancer Monitoring; Sonic Healthcare USA Strengthens Oncology Diagnostics with Acquisition of Cairo Diagnostics

Smart Medical Devices Market Outlook

The Revolution of Healthcare: Smart Medical Devices Transforming the Future

pharma-news-for-madrigal-valneva-protagonist

Madrigal Wins EU Approval for REZDIFFRA in MASH With Liver Fibrosis; Valneva Faces FDA License Suspension for Chikungunya Vaccine IXCHIQ; Coya Secures FDA IND Clearance for COYA 302 in ALS Treatment; Rusfertide Earns FDA Breakthrough Therapy Designation for Polycythemia Vera; Crinetics Gains FDA Orphan Drug Status for Atumelnant in Congenital Adrenal Hyperplasia

emerging-hemophilia-a-therapies-beyond-factor-viii

Hemophilia A Beyond Standard Factor Therapies: Can Gene Therapy, anti-TFPI, and siRNA Siege HEMLIBRA and ALTUVIIIO’s Throne?

vertex-crispr-gene-editing-therapy-exa-cel

Vertex & CRISPR Therapeutics Make History: FDA Approves exa-cel, the First CRISPR Gene Therapy for Sickle Cell and Beta-Thalassemia

besremi-jakafi-rusfertide-for-polycythemia-vera-treatment

Polycythemia Vera: Growing Competition and the Changing Treatment Landscape in 2025

bispecific-antibodies-for-multiple-myeloma-treatment

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Abeona Secures FDA Nod for ZEVASKYN, the First Gene Therapy for RDEB; AbbVie Gains FDA Approval for RINVOQ in Giant Cell Arteritis; Lantern Pharma Advances LP-184 with IND Clearance for TNBC Trial; Ichnos Glenmark Earns FDA Fast Track for ISB 2001 in Multiple Myeloma; Rezolute Wins Breakthrough Therapy Designation for Ersodetug in Tumor-Induced Hypoglycemia

pharma-news-for-cellenkos-mirum-soleno

Cellenkos’ CK0801 Granted FDA Orphan Drug Status for Aplastic Anemia; Mirum’s LIVMARLI Gets FDA Nod for Tablet Formulation; SynOx’s Emactuzumab Earns FDA Fast Track for TGCT; Bristol Myers Squibb’s OPDIVO + YERVOY Combo Approved by FDA for First-Line Advanced Liver Cancer; Soleno Launches VYKAT XR, the First FDA-Approved Therapy for PWS-Related Hyperphagia

qfitlia-for-hemophilia-treatment

Sanofi’s Qfitlia Enters the Hemophilia Market—What Sets It Apart?

Revolutionary Advances and Bright New Horizons in Multiple Myeloma Treatment

Revolutionary Advances and Bright New Horizons in Multiple Myeloma Treatment

pharma-news-for-beam-astrazeneca-sanofi

Sanofi’s Qfitlia Becomes First FDA-Approved Therapy for Hemophilia A or B; FDA Approves AstraZeneca’s IMFINZI as First Perioperative Immunotherapy for Bladder Cancer; Beam Therapeutics’ BEAM-302 for AATD Receives FDA Clearance; AstraZeneca’s CALQUENCE Combo Greenlit in EU for Mantle Cell Lymphoma; Ionis’ WAINZUA Wins EU Approval for Hereditary Transthyretin Amyloidosis

car-t-cell-therapies-for-multiple-myeloma

5 Most Promising CAR T-cell Therapies for Multiple Myeloma in Development

medtech-news-for-abanzza-cerus-inspira

ABANZA Secures FDA 510(k) Clearance for WasherCap™ Mini; Cerus Corporation Secures CE Mark for Next-Gen INTERCEPT Illumination Device; Spinal Stabilization Technologies Enrolls First U.S. Patient in IDE Trial for PerQdisc™; Inspira Technologies Reports Positive Clinical Results for AI-Integrated HYLA Blood Sensor; iCAD and RamSoft Partner to Expand ProFound AI Mammography Solutions in North America; Pulnovo Medical Secures Nearly $100M in Series C Funding

pharma-news-for-agios-bridgebio-rigel

Agios’ PYRUKYND SNDA Accepted by FDA for Thalassemia; BridgeBio’s BBO-8520 Gets FDA Fast Track for KRASG12C-Mutated Lung Cancer; Nipocalimab Granted FDA Priority Review for Myasthenia Gravis; Rigel’s R289 Receives FDA Orphan Drug Designation for MDS; Rise Therapeutics Gets FDA IND Clearance for R-5780 in Cancer

emerging-sickle-cell-disease-therapies

7 Sickle Cell Disease Therapies to Keep an Eye on Post-Pfizer’s OXBRYTA Withdrawal

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader